<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>F. Borella | Romualdi Lab</title>
    <link>/author/f.-borella/</link>
      <atom:link href="/author/f.-borella/index.xml" rel="self" type="application/rss+xml" />
    <description>F. Borella</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><copyright>Â© Research Group</copyright><lastBuildDate>Sat, 01 Jan 2022 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/images/icon_hud8b169d6400d4e9e77db720aa3284c6d_12325_512x512_fill_lanczos_center_2.png</url>
      <title>F. Borella</title>
      <link>/author/f.-borella/</link>
    </image>
    
    <item>
      <title>Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis</title>
      <link>/publication/2022-01-01_copy_number_alterati/</link>
      <pubDate>Sat, 01 Jan 2022 00:00:00 +0000</pubDate>
      <guid>/publication/2022-01-01_copy_number_alterati/</guid>
      <description></description>
    </item>
    
    <item>
      <title>FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients</title>
      <link>/publication/tassi-2019584/</link>
      <pubDate>Tue, 01 Jan 2019 00:00:00 +0000</pubDate>
      <guid>/publication/tassi-2019584/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study</title>
      <link>/publication/calura-2019/</link>
      <pubDate>Tue, 01 Jan 2019 00:00:00 +0000</pubDate>
      <guid>/publication/calura-2019/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
